Investment Outlook For Cell And Gene Therapies Is Cautiously Optimistic
Cell And Gene Therapy Developers Raised $13.3bn In Financing In 2018
Investors at Alliance for Regenerative Medicine’s Investor Day in March 2019 were bullish on cell and gene therapies, but some worry about the market overcrowding.
You may also be interested in...
Investor appetite for cell and gene therapy companies has skyrocketed during the past year. However, storm clouds may gather as manufacturing and reimbursement challenges remain.
Annual payment plans for gene therapies appear closer to becoming reality now that bluebird bio detailed plans at J.P. Morgan. Novartis, Sarepta and others are also talking to payers about alternative payment models. Harvard Pilgrim's Michael Sherman applauded the effort in an interview.
As the pipeline and market for novel cell and gene therapies expands, it is time for drug developers to address other critical aspects in the logistical chain – and for these complex therapies a lot of those issues relate to manufacturing. Looking at specific cases, In Vivo has underlined the main manufacturing challenges facing cell and gene therapy developers, and highlighted methods and approaches being used to generate solutions.